{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:53:24Z","timestamp":1784159604690,"version":"3.55.0"},"reference-count":40,"publisher":"Galenos Yayinevi","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2022,10,28]]},"DOI":"10.4274\/tjo.galenos.2021.20726","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T12:11:09Z","timestamp":1666959069000},"page":"302-308","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists"],"prefix":"10.4274","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-4951","authenticated-orcid":false,"given":"Nilg\u00fcn","family":"Y\u0131ld\u0131r\u0131m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-3521","authenticated-orcid":false,"given":"Banu","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9555-6508","authenticated-orcid":false,"given":"Nur\u015fen","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5981-9657","authenticated-orcid":false,"given":"Halil","family":"Ate\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-8848","authenticated-orcid":false,"given":"Rana","family":"Altan-Yayc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9939-1715","authenticated-orcid":false,"given":"\u00d6zcan","family":"Ocako\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2345-0456","authenticated-orcid":false,"given":"Ay\u015fe","family":"Burcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-0195","authenticated-orcid":false,"given":"Ilgaz","family":"Yalva\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-8470","authenticated-orcid":false,"given":"\u00d6zlem Evren","family":"Kemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-0354","authenticated-orcid":false,"given":"Mehmet","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref0","unstructured":"1. Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82:887-888."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","unstructured":"2. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.","journal-title":"Arch Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003","article-title":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options","volume":"101","author":"authors listed","year":"2017","unstructured":"3. No authors listed. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101:130-195.","journal-title":"Br J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","unstructured":"4. Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, Na KS, Schaumberg D, Uchino M, Vehof J, Viso E, Vitale S, Jones L. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15:334-365.","journal-title":"Ocul Surf"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","unstructured":"5. Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, Gupta PK, Karpecki P, Lazreg S, Pult H, Sullivan BD, Tomlinson A, Tong L, Villani E, Yoon KC, Jones L, Craig JP. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15:539-574.","journal-title":"Ocul Surf"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"694","DOI":"10.5301\/ejo.5000977","article-title":"Ocular Surface Disease in Patients under Topical Treatment for Glaucoma","volume":"27","author":"P\u00e9rez-Bartolom\u00e9","year":"2017","unstructured":"6. P\u00e9rez-Bartolom\u00e9 F, Mart\u00ednez-de-la-Casa JM, Arriola-Villalobos P, Fern\u00e1ndez-P\u00e9rez C, Polo V, Garc\u00eda-Feijo\u00f3 J. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. Eur J Ophthalmol. 2017;27:694-704.","journal-title":"Eur J Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40265-017-0843-9","article-title":"Preservative-Free Prostaglandin Analogs and Prostaglandin\/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages","volume":"78","author":"Hollo","year":"2018","unstructured":"7. Hollo G, Katsanos A, Boboridis KG, Irkec M, Konstas AGP. Preservative-Free Prostaglandin Analogs and Prostaglandin\/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. Drugs. 2018;78:39-64.","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","article-title":"Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting","volume":"11","author":"Baudouin","year":"2013","unstructured":"8. Baudouin C, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246-258.","journal-title":"Ocul Surf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","article-title":"Ocular Surface Disease and Glaucoma Medications: A Clinical Approach","volume":"45","author":"Zhang","year":"2019","unstructured":"9. Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach. Eye Contact Lens. 2019;45:11-18.","journal-title":"Eye Contact Lens"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","unstructured":"10. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418-423.","journal-title":"Br J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4274\/tjo.galenos.2019.29000","article-title":"Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost","volume":"50","author":"Kumar","year":"2020","unstructured":"11. Kumar S, Singh T, Ichhpujani P, Vohra S, Thakur S. Correlation of Ocular Surface Disease and Quality of Life in Indian Glaucoma Patients: BAC-preserved versus BAC-free Travoprost. Turk J Ophthalmol. 2020;50:75-81.","journal-title":"Turk J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/OPX.0000000000000542","article-title":"Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives","volume":"92","author":"Ramli","year":"2015","unstructured":"12. Ramli N, Supramaniam G, Samsudin A, Juana A, Zahari M, Choo MM. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives. Optom Vis Sci. 2015;92:222-226.","journal-title":"Optom Vis Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung","year":"2008","unstructured":"13. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.","journal-title":"J Glaucoma"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","unstructured":"14. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009;19:572-579.","journal-title":"Eur J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.2147\/OPTH.S264984","article-title":"Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients","volume":"14","author":"Ruangvaravate","year":"2020","unstructured":"15. Ruangvaravate N, Choojun K, Srikulsasitorn B, Chokboonpiem J, Asanatong D, Trakanwitthayarak S. Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients. Clin Ophthalmol. 2020;14:3109-3119.","journal-title":"Clin Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.2147\/OPTH.S269586","article-title":"Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments","volume":"14","author":"Stalmans","year":"2020","unstructured":"16. Stalmans I, Lemij H, Clarke J, Baudouin C, GOAL study group. Signs and Symptoms of Ocular Surface Disease: The Reasons for Patient Dissatisfaction with Glaucoma Treatments. Clin Ophthalmol. 2020;14:3675-3680.","journal-title":"Clin Ophthalmol"},{"key":"ref16","unstructured":"17. Saini M, Vanathi M, Dada T, Agarwal T, Dhiman R, Khokhar S. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy. Int J Ophthalmol. 2017;10:931-938."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1089\/jop.2017.0104","article-title":"High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand","volume":"34","author":"Ruangvaravate","year":"2018","unstructured":"18. Ruangvaravate N, Prabhasawat P, Vachirasakchai V, Tantimala R. High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand. J Ocul Pharmacol Ther. 2018;34:387-394.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","unstructured":"19. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341-349.","journal-title":"Eur J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/ceo.13329","article-title":"0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride","volume":"46","author":"Wong","year":"2018","unstructured":"20. Wong TT, Aung T, Ho CL. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride. Clin Exp Ophthalmol. 2018;46:1028-1034.","journal-title":"Clin Exp Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00184009","article-title":"Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma","volume":"232","author":"de Jong","year":"1994","unstructured":"21. de Jong C, Stolwijk T, Kuppens E, de Keizer R, van Best J. Topical timolol with and without benzalkonium chloride: epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1994;232:221-224.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/bjophthalmol-2017-311544","article-title":"Preservatives in glaucoma medication","volume":"102","author":"Steven","year":"2018","unstructured":"22. Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol 2018;102:1497-1503.","journal-title":"Br J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Baudouin C, Renard JP, Nordmann JP, Denis P, Lachkar Y, Sellem E, Rouland JF, Jeanbat V, Bou\u00e9e S. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012.","DOI":"10.5301\/ejo.5000181"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","article-title":"Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases","volume":"27","author":"Dubrulle","year":"2018","unstructured":"24. Dubrulle P, Labb\u00e9 A, Brasnu E, Liang H, Hamard P, Meziani L, Baudouin C. Influence of Treating Ocular Surface Disease on Intraocular Pressure in Glaucoma Patients Intolerant to Their Topical Treatments: A Report of 10 Cases. J Glaucoma. 2018;27:1105-1111.","journal-title":"J Glaucoma"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","article-title":"Chronic Brimonidine Study Group","volume":"115","author":"Schuman","year":"1997","unstructured":"25. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847-852.","journal-title":"Arch Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/IJG.0b013e3182953aef","article-title":"Brimonidine allergy presenting as vernal-like keratoconjunctivitis","volume":"24","author":"Shah","year":"2015","unstructured":"26. Shah AA, Modi Y, Thomas B, Wellik SR, Galor A. Brimonidine allergy presenting as vernal-like keratoconjunctivitis. J Glaucoma. 2015;24:89-91.","journal-title":"J Glaucoma"},{"key":"ref26","unstructured":"27. Bozkurt B, \u0130rke\u00e7 M. Allergic Conjunctivitis and Elevated Intraocular Pressure Associated with The Use of Brimonidine Tartrate 0.2%. Glo-Kat. 2006;1:67-69."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.6.1.45","article-title":"The side effects of the prostaglandin analogues","volume":"6","author":"Hollo","year":"2007","unstructured":"28. Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45-52.","journal-title":"Expert Opin Drug Saf"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1527-3466.2005.tb00168.x","article-title":"Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy","volume":"23","author":"Chen","year":"2005","unstructured":"29. Chen J, Dinh T, Woodward DF, Holland M, Yuan YD, Lin TH, Wheeler LA. Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy. Cardiovasc Drug Rev. 2005;23:231-246.","journal-title":"Cardiovasc Drug Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1167\/iovs.04-1331","article-title":"In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells","volume":"46","author":"Guenoun","year":"2005","unstructured":"30. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-2450.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","unstructured":"31. Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, Horwath-Winter J, Kim T, Mehta JS, Messmer EM, Pepose JS, Sangwan VS, Weiner AL, Wilson SE, Wolffsohn JS. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511-538.","journal-title":"Ocul Surf"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/ceo.12431","article-title":"Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease","volume":"43","author":"Goldberg","year":"2015","unstructured":"32. Goldberg I, Graham SL, Crowston JG, d'Mellow G; Australian and New Zealand Glaucoma Interest Group. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease. Clin Exp Ophthalmol. 2015;43:214-220.","journal-title":"Clin Exp Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IIO.0000000000000232","article-title":"Ocular surface disease in the glaucoma patient","volume":"58","author":"Banitt","year":"2018","unstructured":"33. Banitt M, Jung H. Ocular surface disease in the glaucoma patient. Int Ophthalmol Clin. 2018;58:23-33.","journal-title":"Int Ophthalmol Clin"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00417-020-05067-y","article-title":"Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study","volume":"259","author":"CC","year":"2021","unstructured":"34. Su CC, Lee YC, Lee PRC. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study. Graefes Arch Clin Exp Ophthalmol. 2021;259:1243-1251.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1097\/IJG.0000000000001659","article-title":"Management of Ocular Surface Disease in Glaucoma: A Survey of Canadian Glaucoma Specialists","volume":"29","author":"Muzychuk","year":"2020","unstructured":"35. Muzychuk A, Racine L, Robert MC, Birt C, Penner V, Harasymowycz P, Crichton A, Ford B, Gooi P, Harissi-Dagher M. Management of Ocular Surface Disease in Glaucoma: A Survey of Canadian Glaucoma Specialists. J Glaucoma. 2020;29:1162-1172.","journal-title":"J Glaucoma"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/OPTH.S229815","article-title":"Impact of Ocular Surface Disease Treatment in Patients with Glaucoma","volume":"14","author":"Mylla Boso","year":"2020","unstructured":"36. Mylla Boso AL, Gasperi E, Fernandes L, Costa VP, Alves M. Impact of Ocular Surface Disease Treatment in Patients with Glaucoma. Clin Ophthalmol. 2020;14:103-111.","journal-title":"Clin Ophthalmol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/14656566.2018.1479742","article-title":"1% in ocular surface disease","volume":"19","author":"KG","year":"2018","unstructured":"37. Boboridis KG, Konstas AGP. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. Expert Opin Pharmacother. 2018;19:1027-1039.","journal-title":"Expert Opin Pharmacother"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/eye.2015.40","article-title":"Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications","volume":"29","author":"Saini","year":"2015","unstructured":"38. Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015;29:808-814.","journal-title":"Eye (Lond)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/APO.0b013e31828372c2","article-title":"Burden of Ocular Surface Disease in Patients With Glaucoma From Australia","volume":"2","author":"Chan","year":"2013","unstructured":"39. Chan CC, Crowston JG, Tan R, Marin M, Charles S. Burden of Ocular Surface Disease in Patients With Glaucoma From Australia. Asia Pac J Ophthalmol (Phila). 2013;2:79-87.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12913-018-2836-0","article-title":"The economic impact of sight loss and blindness in the UK adult population","volume":"18","author":"Pezzullo","year":"2018","unstructured":"40. Pezzullo L, Streatfeild J, Simkiss P, Shickle D. The economic impact of sight loss and blindness in the UK adult population. BMC Health Serv Res. 2018;18:63.","journal-title":"BMC Health Serv Res"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:02:47Z","timestamp":1721998967000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2021.20726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2021.20726","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}